MDRNA Cuts Deal With Roche

Xconomy Seattle — 

MDRNA, the Bothell, WA-based developer of RNA interference drugs, said today it has agreed to license part of its technology for a one-time, non-refundable execution fee from Swiss drug giant Roche. The deal is non-exclusive to Roche, although MDRNA said it will provide enough capital for the company to pursue other non-exclusive licensing and financing opportunities.Shares of MDRNA (NASDAQ: MRNA) climbed by more than 30 percent, to 33 cents, after the announcement. The company has been running low on cash.